Saved local watchlist · Deprioritization mentions · sorted by registry update date
Candidate queue
877 active trial–asset records · showing latest 25 · no composite ranking
An ingestion window is pending. Refresh resumes the next page.
| Asset / trial | Sponsor / phase | Status / stopping reason | Independent scores | Source |
|---|---|---|---|---|
| PamidronateNCT00022841 | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)PHASE1, PHASE2 | TERMINATED Inadequate eligible subjects to expect sufficient numbers to analyse outcomes. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-12-19 |
| oregovomabNCT00050375 | Unither PharmaceuticalsPHASE3 | TERMINATED Study closed by sponser | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2007-12-18 |
| oregovomabNCT00034138 | Unither PharmaceuticalsPHASE1, PHASE2 | TERMINATED closed by sponser | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-12-18 |
| oregovomabNCT00034372 | Unither PharmaceuticalsPHASE2 | TERMINATED closed by sponser | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-12-18 |
| oregovomabNCT00086632 | Unither PharmaceuticalsPHASE2 | TERMINATED closed by sponser | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-12-18 |
| RivastigmineNCT00134953 | NovartisPHASE3 | TERMINATED The Principal Investigator left the clinic and there was no one who could take over this study. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-12-17 |
| Dextro-AmphetaminNCT00572767 | Reha RheinfeldenPHASE4 | TERMINATED Intended length of study ended | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-12-13 |
| 0.9% Sodium Chloride, USPNCT00137293 | Wyeth is now a wholly owned subsidiary of PfizerPHASE2 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-12-10 |
| GAP-486 (ZP-123)NCT00137293 | Wyeth is now a wholly owned subsidiary of PfizerPHASE2 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-12-10 |
| 0.9% Sodium Chloride, USPNCT00137332 | Wyeth is now a wholly owned subsidiary of PfizerPHASE2 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-12-10 |
| GAP-486 (ZP-123)NCT00137332 | Wyeth is now a wholly owned subsidiary of PfizerPHASE2 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-12-10 |
| SCA-136NCT00420706 | Wyeth is now a wholly owned subsidiary of PfizerPHASE1 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-12-10 |
| topiramateNCT00243984 | Northeastern Ohio Universities College of MedicinePHASE3 | SUSPENDED Study was discontinued because of high drop out rate. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-12-10 |
| ezetimibe/simvastatinNCT00267267 | PfizerPHASE3 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential20 Operational complexity80 Licensing attractivenessUnknown | Registry evidence2007-12-10 |
| torcetrapib/atorvastatinNCT00267267 | PfizerPHASE3 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential20 Operational complexity80 Licensing attractivenessUnknown | Registry evidence2007-12-10 |
| CMD-193NCT00257881 | Wyeth is now a wholly owned subsidiary of PfizerPHASE1 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-12-10 |
| AcetylcysteineNCT00569465 | University of Turin, ItalyPHASE4 | TERMINATED End of the study | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-12-07 |
| ArginineNCT00569465 | University of Turin, ItalyPHASE4 | TERMINATED End of the study | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-12-07 |
| ATN-161NCT00131651 | AttenuonPHASE2 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-12-06 |
| ThalidomideNCT00314665 | University of CincinnatiPHASE4 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-12-06 |
| DVS-233NCT00301431 | Wyeth is now a wholly owned subsidiary of PfizerPHASE2, PHASE3 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential20 Operational complexity80 Licensing attractivenessUnknown | Registry evidence2007-12-05 |
| Sodium chloride injection USP (0.9%)NCT00195312 | Wyeth is now a wholly owned subsidiary of PfizerPHASE1 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-12-05 |
| IL-12 DNA (formulated with bupivacaine)NCT00195312 | Wyeth is now a wholly owned subsidiary of PfizerPHASE1 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-12-05 |
| IL-15 DNA (formulated with bupivacaine)NCT00195312 | Wyeth is now a wholly owned subsidiary of PfizerPHASE1 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-12-05 |
| HIV-1 gag DNA (formulated with bupivacaine)NCT00195312 | Wyeth is now a wholly owned subsidiary of PfizerPHASE1 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-12-05 |
Recent ingestion runs
| Source | Studies seen | Candidate writes | Status / finished |
|---|---|---|---|
| pubmed | 240 | 100 | finished2026-09-21T03:58:28.397783+00:00 |
| pubmed | 0 | 0 | failed2026-09-21T03:48:59.232056+00:00 |
| sec | 0 | 0 | finished2026-09-21T03:48:59.212906+00:00 |
| ClinicalTrials.gov | 300 | 258 | partial2026-09-21T03:48:59.189357+00:00 |
| ClinicalTrials.gov | 300 | 305 | Legacy run2026-09-21T03:45:47.341408+00:00 |
| ClinicalTrials.gov | 300 | 348 | Legacy run2026-09-21T03:38:48.082427+00:00 |